Regulatory Monitoring Services

The broad areas of application of nanotechnologies, ranging from crop optimisation to cosmetics, are under the scrutiny of regulatory authorities worldwide that develop regulations that impact nanotechnology industries across the planet.

NIA provides its Members with Regulatory Monitoring Services, thus allowing a better understanding of the rules in application. Numerous regulations already specifically target nanotechnologies and set guidelines that manufacturers, importers and distributors of nanomaterials and products containing nanomaterials have to comply with. Through its Regulatory Monitoring Services, NIA provides information for its Members to act in accordance with the legislation in force where they operate. In addition, NIA monitors the legislative process and its upcoming deadlines, NIA Members are alerted on the most significant regulatory outbreaks via NIA’s Regulatory Monitoring Database.

 

Follow this link to access the Database, and this link to subscribe to the service. More information can be found here

Related Links

News & Alerts

WHO publishes Guidelines on Protecting Workers from Potential Risks of Manufactured Nanomaterials

The World Health Organisation (WHO) has recently published Guidelines on Protecting Workers from Potential Risks of Manufactured Nanomaterials (MNM). This document, intended for policy makers and occupational health and safety professionals contains recommendations on ‘how best to protect workers from the potential risks of MNMs’ but are ‘not intended as a handbook or manual for safe handling of MNMS in the workplace’.

US FDA publishes Draft Guidance for Industry on Drug Products, Including Biological Products, that Contain Nanomaterials

The United States Federal Drug Administration has published a draft Guidance on Drug Products, Including Biological Products, that Contain Nanomaterials on 18 December 2017.

This Guidance for Industry outlines potential risk factors for drugs containing nanomaterials. It also provides recommendations on quality aspects, environmental impact as well as guidance for both non-clinical and clinical testing.

The document is now open for public comments for a period of 90 days, closing on 19 March 2018.